Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.
Dasom (Caroline) Lee, MD
Advertisement
Dasom (Caroline) Lee, MD, is a fellow in the Hematology and Medical Oncology Fellowship Program at Stanford Medicine, Stanford Health Care.
Articles by Dasom (Caroline) Lee, MD
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5